Pharmaxis’ first commercial product, the innovative Aridol lung function test, is designed to help doctors diagnose and manage asthma by detecting active airway inflammation through measuring airway hyper-responsiveness. By having patients inhale Aridol via a simple hand-held device, doctors may determine the severity of a patient’s inflammation and prescribe the right amount of medication to bring it under control. The Aridol challenge test potentially prevents inappropriate treatment and may help patients better comply with their therapies. Asthma affects over 52 million people worldwide.
The company’s first product, Aridol, is approved for sale in Australia, major European countries and Korea. It is the first and only approved Europe-wide lung function test and the world’s first approved indirect challenge test for asthma.
Aridol is involved in investigator-sponsored clinical trials worldwide, treating thousands of patients. It has also been included in both international and Australian official guidelines for managing asthma — recognition and endorsement by both global and Australian experts that Aridol is a significant addition to the tools available to help asthma patients. Bodies and guidelines endorsing Aridol include:
